Covaxin | Bharat Biotech
Covaxin neutralizes coronavirus variants found in India, UK
Hyderabad/IBNS: Bharat Biotech has announced that Covid-19 vaccine - COVAXIN, produced neutralising titres (concentration) against all key emerging variants tested, including the B.1.617 and B.1.1.7, first found in India and the United Kingdom.
The company, in an infographic showed, a modest reduction in neutralisation by a factor of 1.95 was seen against the B.1.617 variant compared to the vaccine variant (D614G), said a Hindustan Times report.
It added that though there was reduction, neutralizing titre levels with B.1.617 did not fall and were detected above levels expected to be protective.
"No difference in neutralization between B.1.1.7 (first found in the UK) and vaccine strain (D614G) was observed," Bharat Biotech added.
These findings were revealed in collaboration with National Institute of Virology - India Council of Medical Research.
COVAXIN is indegenously developed and manufacture in India and is one of the three Covid-19 vaccines that are currently available in the country, the other two being Russia's Sputnik V and Serum Institute of India's Covishield.
As per the Union Health Ministry, a total of 18,22,20,164 doses of Covid-19 vaccines have been given across the country so far.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
